Area of research
Infectious Diseases · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Monoclonal and Polyclonal Antibodies Research, and SARS-CoV-2 detection and testing.
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
Durability of immune responses to mRNA booster vaccination against COVID-19
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Defining the risk of SARS-CoV-2 variants on immune protection
Durability of immune responses to the BNT162b2 mRNA vaccine
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
Antagonism of the Phosphatase PP1 by the Measles Virus V Protein Is Required for Innate Immune Escape of MDA5
Measles Virus Suppresses RIG-I-like Receptor Activation in Dendritic Cells via DC-SIGN-Mediated Inhibition of PP1 Phosphatases